Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Receivables (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Change in Receivables for 7 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 463.14% year-over-year to -$5.7 million, compared with a TTM value of -$4.6 million through Dec 2025, down 220.61%, and an annual FY2025 reading of -$4.6 million, down 220.61% over the prior year.
  • Change in Receivables was -$5.7 million for Q4 2025 at Karyopharm Therapeutics, down from -$1.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $6.9 million in Q2 2024 and bottomed at -$11.9 million in Q1 2023.
  • Average Change in Receivables over 5 years is -$310400.0, with a median of $89500.0 recorded in 2021.
  • The sharpest move saw Change in Receivables soared 358.61% in 2022, then crashed 8219.26% in 2023.
  • Year by year, Change in Receivables stood at $3.7 million in 2021, then plummeted by 96.4% to $135000.0 in 2022, then plummeted by 8219.26% to -$11.0 million in 2023, then soared by 90.77% to -$1.0 million in 2024, then plummeted by 463.14% to -$5.7 million in 2025.
  • Business Quant data shows Change in Receivables for KPTI at -$5.7 million in Q4 2025, -$1.1 million in Q3 2025, and -$2.3 million in Q2 2025.